Publication

Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA)

ANNÉE

2017

AUTEURS

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Boige V, Taieb J, Bouche O, Francois E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Lepage C, Aparicio T, Hoeffe C

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3601

Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial

ANNÉE

2017

AUTEURS

Schernberg A, Vernerey D, Goldstein D, Laethem J, Glimelius B, Houtte P, Bonnetain F, Louvet C, Hammel P, Huguet F

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4120

ANNÉE

2017

AUTEURS

Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T

CONGRÈS/REVUE

Eur J Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.ejca.2017.07.038

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial

ANNÉE

2017

AUTEURS

Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T

CONGRÈS/REVUE

PLoS One

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1371/journal.pone.0183288

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours

ANNÉE

2017

AUTEURS

Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2017.02.004

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

ANNÉE

2017

AUTEURS

Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, Vendrely V, Francois E, de La Roche G, Bouche O, Mirabel X, Denis B, Mineur L, Berdah J, Mahe M, Becouarn Y, Dupuis O, Lledo G, Seitz J, Bedenne L, Gourgou-Bourgade S, Juzyna B, Conroy T, Gerard J

CONGRÈS/REVUE

Ann Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1093/annonc/mdx351

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects

ANNÉE

2017

AUTEURS

Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J

CONGRÈS/REVUE

Eur J Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.ejca.2017.03.036

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

ANNÉE

2017

AUTEURS

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

CONGRÈS/REVUE

Eur J Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.ejca.2017.04.025

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial

ANNÉE

2016

AUTEURS

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C

CONGRÈS/REVUE

JAMA

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1001/jama.2016.4324

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

ANNÉE

2016

AUTEURS

Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F

CONGRÈS/REVUE

Br J Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1038/bjc.2016.212